Results 171 to 180 of about 1,440 (183)

Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) – a new perspective

Leukemia and Lymphoma, 2021
Rayaz Ahmed, Dinesh Bhurani, Vishvdeep Khushoo   +2 more
exaly  

Cytogenetic Findings in a Case of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Journal of the Association of Genetic Technologists
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as natural killer (NK) cell leukemia/lymphoma, is categorized by the World Health Organization as a sole entity. Most often, BPDCN presents with features of both lymphoma and leukemia. The average age at diagnosis is 60 to 70 years and there are more men than women who are diagnosed
Carlos A, Tirado, John, Reinartz, Katherine, Lapp, Diane, Zhao, Andrew M, Nguyen, Kevin, Stieglbauer   +5 more
openaire   +1 more source

BPDCN: die frühe Diagnose ist entscheidend

Schweizerische Ärztezeitung
Werner Kempf, Antonio Cozzio, Stefan Dirnhofer, Emmanuella Guenova, Vera Ulrike Bacher, Mathias Schmid, Gerasimos Tsilimidos, Sabine Blum, Alexandre Theocharides   +8 more
openaire   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN)

2017
openaire   +1 more source

Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

Current Hematologic Malignancy Reports, 2017
Naveen Pemmaraju
exaly  

CD123-Targeted Therapy Shows Long-Term Benefit for BPDCN Patients

Oncology Times, 2022
openaire   +1 more source

Clinical Hold Lifted on UCART123 Trials for AML/BPDCN

Oncology Times, 2017
openaire   +1 more source

Primary Cutaneous Presentation of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

European Journal of Cancer
Ch. Oikonomidi, Anthi Bouchla, Kyriaki Lampadaki, Leonidas Marinos, Evangelia Papadavid, Vasiliki Pappa   +5 more
openaire   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCNs)

openaire   +1 more source

CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

Leukemia Research
Brent Tan, Naveen Pemmaraju, Atif Saleem   +2 more
exaly